IGC Pharma, Inc. — News

POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No.

accessnewswire.com - 2026-07-29 08:30:00

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD / ACCESS Newswire / July 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will showcase its artificial intelligence portfolio across seven scientific presentations at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London. IGC Pharma is building computational infrastructure designed to accelerate data integration, patient stratification, and clinical development workflows in Alzheimer's disease.

accessnewswire.com - 2026-07-09 09:00:00

Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Chief Executive Officer Ram Mukunda and Principal Financial Officer Claudia Grimaldi have purchased an aggregate of 4,274,853 shares of IGC common stock directly from the Company at $0.27 per share. The shares were purchased through the cancellation of approximately $1.15 million of outstanding amounts owed by the Company to Mr.

accessnewswire.com - 2026-07-07 09:00:00

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London POTOMAC, MD / ACCESS Newswire / June 23, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease and AI-enabled healthcare technologies, today announced the beta version of its proprietary Agentic Harmonization Assistant ("AHA"), an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer's and aging-related datasets. The announcement comes as IGC advances IGC-AD1, its lead Phase 2 Alzheimer's candidate for agitation associated with Alzheimer's dementia, positioning the Company at the intersection of Alzheimer's therapeutics and AI-enabled pharmaceutical discovery.

accessnewswire.com - 2026-06-23 08:30:00

Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / June 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia has reached the Company's previously disclosed target enrollment of 146 patients, with 146 participants randomized at baseline. The Company's prior enrollment updates described progress toward this 146-patient target.

accessnewswire.com - 2026-06-11 08:30:00

POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share. According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress in 2026 could serve as strong catalysts for IGC Pharma's stock.

accessnewswire.com - 2026-06-09 08:30:00

Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The addition of Mount Sinai comes as CALMA advances toward completion, with approximately 80% of targeted participants having completed trial participation.

accessnewswire.com - 2026-06-02 08:30:00

- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics and artificial intelligence ("AI-enabled") tools for Alzheimer's disease ("AD"), today announced the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission ("SEC") for the quarter ended March 31, 2026. "During the first quarter, we continued to execute against our core priorities by advancing CALMA, expanding our clinical site network, and strengthening the AI and intellectual property components of our Alzheimer's strategy with disciplined capital allocation," said Ram Mukunda, CEO of IGC Pharma.

accessnewswire.com - 2026-05-19 17:30:00

Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington, D.C.

accessnewswire.com - 2026-05-15 08:00:00